Sarah Bhagat, PhD

Sarah Bhagat, PhD

Principal, Private Equity

Sarah joined Sofinnova as an Associate in 2017.  In 2019, she was promoted to Principal. She focuses on biopharmaceutical investments. Sarah currently serves as a Board Member for Inozyme and a Board Observer for Akouos, Antiva, Neurana, and NextCure. Sarah played a central role in Sofinnova’s investments in Apellis (APLS), Pionyr and YmAbs (YMAB), which she previously served as a Board Observer.

Prior to joining Sofinnova, Sarah was a postdoctoral fellow in neuroscience at Stanford University in the laboratories of Drs. Robert Malenka and Karl Deisseroth. As a graduate student at Yale, Sarah worked with Dr. Stephen Strittmatter, her thesis advisor and co-founder of Axerion Therapeutics, to identify novel targets and develop therapeutics for CNS injury and psychiatric disorders. Sarah was also a Venture Fellow for Canaan Partners. Prior to Yale, Sarah worked as a research assistant for The Rockefeller University. Before her time at Rockefeller, Sarah was a Clinical Research Coordinator at Massachusetts General Hospital in the Bipolar Clinic and Research Program.

Sarah received her Ph.D. in Neuroscience from Yale University, where she was a National Science Foundation Graduate Research Fellow. Sarah also holds a B.A. in Biological Psychology from Franklin & Marshall College. Sarah is also an alumna of Stanford’s Graduate School of Business Ignite Entrepreneurship and Innovation Program.

Active Companies